en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2009
vol. 47
 
Share:
Share:
more
 
 
abstract:
Original paper

Antibodies against protective molecules in systemic lupus erythematosus

Dorota Cieślak
,
Ilona Górska
,
Zofia Niemir
,
Paweł Hrycaj

Reumatologia 2009; 47, 6:323-328
Online publish date: 2010/04/08
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Background: Many experiments in vitro and in vivo show that, in patients with SLE, there is impairment in the clearance of apoptotic cells. This leads to prolonged exposure of autoantigens to the immune system and to autoimmunity.
The aim of the study was to investigate the relationship between antibodies against protective molecules and the activity of lupus measured by the SLEDAI scale.
Material and methods: 45 lupus patients were assessed for the presence of protective molecules in lupus and antibodies against these molecules.
Results: Levels of hsCRP and anti-C1q were higher in SLE patients compared to the control group, whereas the level of MBL was statistically lower in the SLE group. There was no correlation between levels of hsCRP, MBL, C1q, C4, anti-C1q or anti-CRP in patients and the activity of the disease.
Conclusions: CRP plays the most important role in the clearance of apoptotic material in SLE, and therefore is protective in lupus. The lower levels of MBL in patients with SLE suggest its protective value in this disease. There was low incidence of the presence of assessed antibodies, and therefore there was no possibility to evaluate their role in SLE.
keywords:

lupus, apoptosis, protective molecules







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.